Skip to main content

Table 1 Baseline characteristics of study population in the CREDIT registry

From: Chinese Registry of rheumatoid arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis

  Total cohort Without comorbidity With comorbidity
Any CVD Fracture Malignancy
N (%) 13,210 (100) 12,651 (95.8) 559 (4.2) 293 (2.2) 222 (1.7) 78 (0.6)
Demographic features
 Female, % 80.6 80.8 77.6 68.6 88.3 80.8
 Age, ya 52.9 ± 13.1 52.4 ± 13.0 62.9 ± 10.8 65.6 ± 9.5 61.0 ± 11.8 60.9 ± 10.4
 Age ≥ 60, % 32.7 31.2 66.9 75.4 61.7 59.0
Clinical characteristics
 RA duration, yb 4.0 (1.3–10.0) 4.0 (1.2–10.0) 6.3 (2.0–13.1) 6.0 (1.4–12.9) 7.7 (3.0–15.7) 4.0 (1.2–10.7)
 RF/CCP+, % 83.6 83.4 86.9 86.0 86.5 89.7
 ESR, mm/hb 34.0 (17.0–60.0) 33.0 (17.0–60.0) 41.0 (21.0–66.0) 40.0 (20.5–67.5) 39.5 (20.8–66.0) 45.0 (22.8–65.0)
 CRP, mg/Lb 10.3(3.2–30.0) 10.2 (3.2–30.0) 11.5 (3.2–35.8) 12.0 (3.3–39.2) 9.9 (3.2–35.5) 7.7 (2.8–29.7)
 DAS28-CRPa 4.5 ± 1.7 4.4 ± 1.7 4.7 ± 1.7 4.7 ± 1.7 4.7 ± 1.8 4.6 ± 1.8
Medications
 GC ever, % 40.6 40.5 43.1 46.1 41.9 34.6
 MTX ever, % 55.9 56.4 44.7 42.3 47.7 37.2
 bDMARDs, % 8.3 8.2 9.3 8.9 14.4 1.3
  1. CVD cardiovascular disease, RA rheumatoid arthritis, RF rheumatoid factor, CCP anti-citrullinated protein antibody, DAS28 disease activity score 28, ESR erythrocyte sedimentation rate, CRP C-reactive protein, GC glucocorticoid, MTX methotrexate, bDMARDs biological disease-modifying antirheumatic drugs
  2. aData are presented as mean ± SD (standard deviation)
  3. bData are presented as median (IQR, interquartile range)